Kornimate/medical-research-clean huggingface dataset:
etiology, epidemiology and prognostics of acute kidney injury (aki)

Conditions: Renal Failure; Nutrition Disorders

Summary: * to investigate the etiology, epidemiology and prognostic factors of acute kidney injury. * to find out risk factors that relate with the prognosis of acute kidney injury,focusing on inflammation, oxidative stress and nutritional status. * to study on the relationship between gene polymorphism and prognosis of acute kidney injury.

1. to investigate the relationship between preexisting malnutrition and adverse outcomes in patients with aki - several nutritional assessment methods such as anthropometric, clinical and biochemical evaluations have been used; however, no single indicator is considered to be a "gold standard." 2. to evaluate the association of serum nutritional variables and prognosis of acute kidney injury 3. given the different half-lives of serum nutritional markers, we hypothesized that the utility of serum nutritional variables as prognostic predictors may differ in early death (\ 7 days, \<28 days) patients.

Eligibility criteria:
inclusion criteria: * age \>=16 years and \<= 88 years * clinically diagnosed with acute kidney injury, according rifle or kdigo criteria. exclusion criteria: * acute renal failure occurring in the setting of burns, obstructive uropathy, allergic interstitial nephritis, acute or rapidly progressive glomerulonephritis, vasculitis, hemolytic-uremic syndrome, thrombotic thrombocytopenic purpura (ttp), malignant hypertension, scleroderma renal crisis, atheroembolism, functional or surgical nephrectomy, hepatorenal syndrome, cyclosporin or tacrolimus nephrotoxicity * do not resuscitate (dnr) status * subjects enrolled in another clinical trial that could affect the outcome of this study protocol

Keywords: acute kidney disease prognosis oxidative stress inflammation gene polymorphism
comparison of the effects of dapagliflozin and gemigliptin on ketone metabolism and cardiac remodeling in type 2 diabetes

Conditions: Type2 Diabetes; Remodeling, Ventricular

Summary: sodium-glucose cotransporter 2 (sglt2) inhibitors have demonstrated cardiovascular and renal protection in patients with type 2 diabetes (t2d); however, the underlying mechanism remains unclear. we hypothesized that sglt2 inhibitor will improve the ketone metabolism compared to dipeptidyl peptidase-4 (dpp4) inhibitor. and we will also evaluate the association between ketone metabolism and cardiac remodeling evaluated by echocardiography. we will randomly assign 122 people with t2dm to receive dapagliflozin 10mg or gemigliptin 50mg. the primary endpoint are changes in acetoacetate, total ketone, beta-hydroxybutyric acid, left ventricular (lv) mass index, and lv global longitudinal strain during 6 months follow-up. this study may provide robust evidence of the thrifty substrate hypothesis for cardiovascular protection of sglt2 inhibitors.


Eligibility criteria:
inclusion criteria: * subjects diagnosed with t2d on stable antidiabetic medication * no recent use of sglt2 inhibitor within 3 months exclusion criteria: * hba1c \> 10% * pregnancy or breast feeding * estimated gfr \<45 30 ml/min/1.73㎡ * insulin user
snp-based prediction of recurrence risk in kidney stone patients

Conditions: Kidney Stone

Summary: the goal of this study is to gain new knowledge about genetic risk factors that may affect the kidney stone recurrence. the study seeks to understand if different forms of genes result in an increased risk of kidney stone recurrence.

in this study, investigators are prospectively testing whether snp are associated with kidney stone recurrence. investigators will test the hypothesis that snp predispose kidney stone patients to recurrence. investigators hope to identify predictors for the kidney stone recurrence. this would allow the identification of a subpopulation of kidney stone patients that would benefit most from prevention measures.

Eligibility criteria:
inclusion criteria: * age 18 or older * kidney stone former who the stone was removed completely. * ability to give informed consent exclusion criteria: * patient refuses or is unable to give consent

Keywords: snp kidney stone recurrence
uva islet cell transplantation in patients with type i diabetes

Conditions: Diabetes Mellitus, Type 1

Summary: this protocol will provide islet cell transplantation to two separate populations in need of a pancreas transplant: group i: islet cell transplantation in type i diabetics without kidney problems group ii: islet cell transplantation in type i diabetics who have a stable functioning kidney transplant the targeted patients have very brittle diabetes or dangerous hypoglycemic unawareness and may benefit from transplantation over continuing insulin therapy, even though chronic immunosuppression is required. we believe that in these patients, the islet transplant procedure promises enough potential benefit to justify subjecting patients who have not previously had a transplant to the risk of immunosuppression. in patients who are already subject to the dangers of chronic immunosuppression for other reasons, i.e. to prevent rejection of a kidney allograft, the islet transplantation procedure itself is the principal additional risk and this risk should be minimal. in these patients (our group ii), the potential benefit from improved glycemic control is that it promises to slow or even reverse diabetic complications, such as vascular problems leading to kidney damage. it is this rationale that has made pancreas transplantation a widely accepted option in patients with renal failure, despite the risks associated with whole pancreas transplantation. islet cell transplantation aims to provide a potentially lower risk procedure that has similar relief from diabetic complications.


Eligibility criteria:
inclusion criteria: * type i diabetes mellitus for at least 5 years * unstable control of diabetes despite intensive care by an endocrinologist, including episodes of dangerously low blood sugars * group i must have healthy kidneys * group ii (islet after kidney) must have a stable kidney allograft for at least 6 months exclusion criteria: * unstable diabetic eye disease * poor kidney function * type ii diabetes as determined by blood tests * any history of cancer, except certain skin cancers * pregnant or unwilling to use adequate birth control * very high hemoglobin a1c levels * poor control of blood pressure, despite use of medications * very high insulin requirements * history of exposure to hiv * active hepatitis b or hepatitis c infection

Keywords: type 1 diabetes kidney transplant hypoglycemic unawareness islet transplant pancreatic islet cell transplantation university of virginia islet transplantation kidney transplantation
effect of menopausal hormone therapy on immune system parameters

Conditions: Last Period Not Earlier Than 6 Months Ago

Summary: the objective of the study is to evaluate the effect of menopausal hormone therapy on the parameters of the immune system. to do this, patients took blood to assess the immune status before the start of therapy and after 3 months. an additional task is to assess the content of blood sex hormones before the start of therapy and after 3 months.

a study of 60 perimenopausal and postmenopausal patients was included. the cohort was divided into groups depending on the treatment regimen. group 1 (n=20) received transdermal menopausal hormone therapy (mht). group 2 (n=20) received oral mht.

Eligibility criteria:
inclusion criteria: * age from 45 to 59; * phase of reproductive aging - perimenopause, postmenopause or surgical menopause (ovariectomy); * indications for prescribing mht exclusion criteria: 1. absolute contraindications to mht: * bleeding from the genital tract of unknown origin * breast and endometrial cancer * acute hepatitis * acute deep vein thrombosis * acute thromboembolism * cutaneous porphyria 2. obesity; 3. hiv infection and other congenital and acquired immunodeficiencies; 4. systemic connective tissue diseases; 5. oncological diseases in history; 6. history of chemotherapy and/or radiation therapy; 7. autoimmune diseases; 8. acute diseases and exacerbation of chronic diseases during the last 3 months; 9. reception of immunomodulatory drugs during the last 3 months.

Keywords: immune status menopausal hormone therapy
registry study of the ndo surgical plicator for the treatment of gerd

Conditions: GERD

Summary: the purpose of this study is to collect post-marketing data on patient outcomes and satisfaction following treatment with the plicator™. the outcomes will be tracked through analysis of patient quality of life (qol) questionnaires and medication use. the qol and medication use questionaires will be administered and documented twice before the procedure and then again at outlined intervals following the procedure. additionally, financial measures will be evaluated (i.e. pre-procedural and procedural time and costs, staffing/personnel needs during procedure, anesthesia and related costs, recovery time and associated cost, etc.) and post-procedure gerd-related medical history questionnaires will be completed. this post-market evaluation is a multi-center study design using the ndo surgical, inc. plicator as the treatment device. treatment efficacy will be evaluated by comparing qol and medication use before and after treatment with the device. patient follow-ups will be completed at 1 week and at 6, 12, 24, 36, 48 and 60 months post treatment.


Eligibility criteria:
inclusion criteria: * subject is suitable for surgery (american society of anesthesiologists physical status classification i or ii). * subject agrees to study participation and signs/dates an informed consent form. exclusion criteria: * significant esophageal dysmotility as determined by manometry * esophagitis grade iii or iv (savary-miller) * barrett's epithelium * hiatus hernia \> 2cm * persistent dysphagia, weight loss, esophageal bleeding, vomiting, gas or bloating * esophageal or gastric varices * previous endoscopic or surgical anti-reflux procedure * other esophageal or gastric surgery * chronic use of anticoagulant or platelet anti-aggregation therapy (other than for cardiac prophylaxis); and * pregnancy.

Keywords: gastroesophageal reflux disease (gerd) plicator full-thickness plication
retrospective study on prolonged sedation effects with inhaled agents in picu

Conditions: Mechanical Ventilation

Summary: the objective of the study is to evaluate the effects of halogenated gases on sedation and analgesia, to describe the tolerance and to determine the risk factors for failure, in pediatric intensive care patients during prolonged sedation. this study will be based on the medical records of patients hospitalized between 2015 and 2020.

sedation is a major therapeutic element in patients in intensive care under artificial ventilation, in order to allow their comfort and patient-ventilator synchronization. the use of benzodiazepines in combination with opioids is common practice. however, during prolonged sedation, the effects wane, then the doses must be increased, responsible for an increase in the incidence of a significant withdrawal syndrome in the recovery phase, a source of delay in extubation or early reintubation. the use of halogenated anesthetic gases is now possible in pediatric intensive care in these patients on artificial ventilation. their efficacy and tolerance in prolonged use must be evaluated. their use could improve the sedative effects, reduce the doses of benzodiazepines and opioids used, and reduce unwanted effects in terms of withdrawal syndrome. the objective of the study is to evaluate the effects of halogenated gases on sedation and analgesia, to describe the tolerance and to determine the risk factors for failure, in pediatric intensive care patients during prolonged sedation. this study will be based on the medical records of patients hospitalized between 2015 and 2020.

Eligibility criteria:
inclusion criteria: * minor patient over 1 month old (and over 36 wa of corrected age) and under 18 years old * hospitalized in neonatal or pediatric intensive care unit * invasive mechanical ventilation over 72 hours * prolonged sedation greater than 72 hours exclusion criteria: - opposition of the holders of parental authority of the minor patient or the adult patient to the use of the data for the study

Keywords: artificial ventilation pediatric intensive care unit prolonged sedation effects halogenated anesthetic gases inhaled agents benzodiazepines in combination with opioids halogenated anesthetic gases efficacity and tolerance
early cpap and large volume minimally invasive surfactant (ecalmist) in preterm infants with rds

Conditions: Respiratory Distress Syndrome

Summary: modification of minimally invasive surfactant therapy (mist) to a new technique called ecalmist (early cpap and large volume minimal invasive surfactant). this modification is needed to adapt the use of large volume surfactant of 4-5 ml/kg. the ecalmist will be used to deliver the large volume surfactant that been used in canada called bles (about 5 ml for each 100 mg) to the preterm infants bellow 35 weeks gestation suffer from respiratory distress syndrome (rds) in 1st 24 hours of life while maintained on cpap.

the 5 ml/kg surfactant is warm to room temperature. using standard laryngoscope without premedication while the infant is maintained on continuous positive airway pressure (cpap. the the laryngoscope should be removed after stabilizing the vascular catheter between 2 fingers at the level of lips (weight +6 cm). the surfactant will be administer by boluses of 0.25 -0.5 ml at a time over 20-30 seconds and 10 seconds apart while maintain the vital signs. the procedure should be stopped if the vital signs deteriorate, cpap pressure and oxygen requirement might need to adjusted to restore baseline vital signs. if the vital signs remained unstable the catheter should be removed and the infant managed according by positive pressure ventilation (ppv) or intubation by endotracheal tube (ett). at the end of the procedure the catheter should be flushed with 0.5 ml of air then catheter should be removed. fio2 (fraction of inspired oxygen), oxygen saturation and cpap pressure will be recorded before during and after the procedure. complication like bradycardia (hear rate below 100 beat per minute) or apnea (pause of respiration for more than 20 second or less than 20 seconds but associated with bradycardia) all other neonatal outcome will be recorded (ivh \[intra-ventricular hemorrhage\], rop \[retinopathy of prematurity\], duration of ventilation, duration of hospital stay, infection, duration of oxygen requirement and others.

Eligibility criteria:
inclusion criteria: -preterm infants less than 35 weeks gestation in 1st day of life with rds and spontaneously breathing on cpap and need surfactant administration. exclusion criteria: * infants needs of mechanical ventilation * congenital anomaly * respiratory distress due to non rds related causes. * no parental consent

Keywords: respiratory distress syndrome preterm infants vascular catheter surfactant cpap ecalmist
efficacy and safety of mp-424, peginterferon alfa-2b and ribavirin in relapser genotype 2 hepatitis c infected patients

Conditions: Chronic Hepatitis C

Summary: this study will evaluate the efficacy and safety of mp-424 with peginterferon alfa-2b and ribavirin (rbv) in patients with genotype 2 hepatitis c, who relapsed after previous treatment.


Eligibility criteria:
inclusion criteria: * genotype 2, chronic hepatitis c * relapsers (patient who relapsed after previous treatment) * able and willing to follow contraception requirements exclusion criteria: * cirrhosis of the liver or hepatic failure * hepatitis b surface antigen-positive or hiv antibodies-positive * history of, or concurrent hepatocellular carcinoma * history of, or concurrent depression, schizophrenia,; or suicide attempt in the past * pregnant, lactating, or suspected pregnant patients, or male patients whose female partner is pregnant

Keywords: genotype 2
lacosamide versus topiramate in migraine

Conditions: Migraine Disorders

Summary: investigators aim to compare the effect of lacosamide versus topiramate in migraine by assessing the absolute reduction in mmd in each group, the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency.

investigators will enroll 600 migraine patients who are diagnosed according to ichd3-beta criteria in our study and will use a questionnaire to detect their demographic and clinical features (disease duration, attack frequency, and duration, pain intensity assessed by the visual analogic scale and we have two groups the first group will include 300 patients and will receive 50 mg lacosamide twice daily and acetaminophen 500-1000 mg in acute attack, and the second group will receive topiramate100 mg per day and acetaminophen 500-1000 mg in acute attack for at least three months. investigators will assess the number of migraine days after three months of treatment and the percentage of patients who achieved ≥ 50% reduction in the monthly headache days frequency compared to the baseline frequency (14).. hit-6 score reduction in each group after three months of treatment. the safety of lacosamide was evaluated by monitoring and documenting treatment-emergent adverse events (teae) in patients through regular follow-up procedures for three months.

Eligibility criteria:
inclusion criteria: - naive migraine patients, according to the international classification of headache disorders 3rd edition, aged 10-55 years, exclusion criteria: - patients with major neurological disorders such as ( epilepsy, ischemic or hemorrhagic stroke, multiple sclerosis, mitochondrial diseases, brain tumors, and patients with essential tremors. patients with major systemic diseases such as malignancy, collagen, liver, and renal diseases. patients with cardiovascular diseases like hypertension (systolic blood pressure of more than 130 and/or diastolic blood pressure of more than 85 mm/hg on at least three different occasions, diabetes (fasting plasma glucose level \>126 mg/dl and/or a casual plasma glucose \>200 mg/dl and/or hba1c more than 6.5. patients with valvular and ischemic heart diseases, bradycardia or heart blocks, congestive heart failure patients who received prophylactic treatment for migraine, patients with any contraindications to drugs used in the study patients with topiramate or lacosamide contraindications

Keywords: lacosamide topiramate migraine
methodology study to examine 6-week food intake with liraglutide in obese subjects

Conditions: Obesity

Summary: this will be a randomized, double blind, placebo controlled, 2 arm, parallel group, methodology study to assess the effect of 6 weeks of liraglutide administration on food intake in obese subjects.


Eligibility criteria:
inclusion criteria: * males and female subjects; * body mass index 30-40 kg/m2; exclusion criteria: * evidence of history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergises, but excluding untreated, asymptomatic, seasonal allergies at time of dosing)
serratus anterior plane block for pain treatment after video-assisted thoracoscopic surgery

Conditions: Nerve Block

Summary: analgesia following video-assisted thoracoscopic surgery (vats) is important for the prevention of postoperative pulmonary complications.various regional methods of anesthesia are currently being used to achieve this goal. the aim of the study was to assess the effectiveness of sapb on postoperative vats analgesia.


Eligibility criteria:
inclusion criteria: * patients who were in the american society of anesthesiologists (asa) i-iii class and underwent video-assisted thoracoscopic surgery (vats). exclusion criteria: * previous history of opioid use preoperatively, * allergy to local anesthetics, * the presence of any systemic infection, * uncontrolled arterial hypertension, * uncontrolled diabetes mellitus.
the effect of exercise in water on functional fitness in people with parkinson's disease

Conditions: Parkinson; Parkinson Disease; Neurologic Disorder

Summary: the goal of this clinical trial study is to learn about the effect of aquatic exercise in parkinson's patients. the main questions it aims to answer are: * what is the effect of exercise in water on balance in parkinson's patients? * what is the effect of exercise in water on muscle strength in parkinson's patients? * what is the effect of exercise in water on flexibility in parkinson's patients? parkinson's patients in this study will do some functional tests. one group of them will do exercises in water 3 times weekly for 8 weeks.

parkinson's disease (pd) is a progressive, neurodegenerative movement disorder characterised by the motor symptoms bradykinesia, tremor, rigidity, and postural instability. these are commonly associated with non-motor disturbances, neurobehavioural symptoms and reduced quality of life. exercise is currently recommended as an additional strategy to manage pd-induced disability and is a key component of rehabilitation programs for people with pd. aquatic exercise is another form of non-conventional exercise that has been growing in popularity in the context of neurorehabilitation.16 the aquatic setting offers specific mechanical advantages due to the hydrostatic and hydrodynamic principles of buoyancy, viscosity and drag. due to its ability to enhance functional mobility whilst also being enjoyable,aquatic exercise has become a very popular form of physical training in the management of neurodegenerative disorders. recent studies suggest that high-intensity interval training (hiit) is promising for promoting neuroplasticity in human pd, with short training time and reduced burden. biomarkers for neuroplasticity such as brain-derived neurotrophic factor (bdnf) and neurodegeneration (including neurofilament light chain ((nfl) and α-synuclein) may play a role, but their response to hiit is not well-investigated. the aims of this study are to investigate the effects of hiit exercises in water on balance, muscle strength, flexibility and gait speed in pd patients.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of idiopathic pd, from mild to moderate stages (severity from 1 to 4), according to the original version of the hoehn \& yahr scale (hy)17, assessed by the neurologist * having medical certificate for performing physical activities and attending heated pools exclusion criteria: * having another neurological pathology * having limiting orthopedic or heart associated conditions * changing physical activities or l-dopa-based drug intake parameters

Keywords: parkinson disease aqua therapy balance neurological disorders
optimal endoscopic suturing pattern for esophageal stent fixation

Conditions: Esophageal Stenosis; Stent Migration; Suture, Complication

Summary: researchers are trying to determine which suturing pattern for esophageal stent placement is more effective in a randomized fashion as currently what suturing pattern to use is an arbitrary decision.

the participants who are receiving esophageal stent placement will be prospectively randomized to receive two suturing patterns (simple interrupted pattern and triangular pattern) for endoscopic esophageal stent fixation. we will investigate rate of the stent migration at 3-4 weeks by endoscopy after the stent placement as part of routine clinical care. data of the duration of endoscopic suturing, adverse events, details of the stent used, indication for use will also be collected.

Eligibility criteria:
inclusion criteria: * subjects aged 18 or above * subjects undergoing esophageal stent placement with any indication exclusion criteria: * imprisoned individuals, * institutionalized patients * inability or unwillingness of individual

Keywords: esophageal stenosis endoscopic suturing esophageal stent fixation stent migration